SHBG Asp356Asn — When an Extra Sugar Chain Changes Your Hormone Balance
Sex hormone-binding globulin is the liver's principal carrier for testosterone and estradiol.
Only a tiny fraction of circulating testosterone — roughly 1–3% — is truly free and biologically
active; SHBG tightly binds the rest, holding it in reserve. Rs6259 changes one amino acid deep
in SHBG's C-terminal domain, and the consequence is biochemically elegant: the substitution
creates a new site where sugar chains can attach to the protein. That extra glycosylation
extends SHBG's survival in the bloodstream, pushing circulating SHBG concentrations higher —
and shifting the balance between bound and free sex hormones.
The Mechanism
The variant converts aspartate to asparagine at position 356 of the SHBG precursor protein
(position 327 in the older mature-protein numbering, giving rise to the historically common
"Asp327Asn" or "D327N" designation in older literature). Asparagine at this position creates
an [N-linked glycosylation consensus sequence | The sequence motif Asn-X-Ser/Thr, where X is
any amino acid except proline, is recognized by the oligosaccharyltransferase complex in the
endoplasmic reticulum as a site for N-linked sugar chain attachment] that the wild-type
aspartate does not support.
A key nuance: [biochemical studies of SHBG glycosylation | Bocchinfuso et al. Endocrinology
1992, PMID 1425432; Hammond & Bocchinfuso J Steroid Biochem Mol Biol 1995, PMID 7626508]
show that N-linked carbohydrate chains do NOT alter SHBG's steroid-binding affinity for
testosterone or dihydrotestosterone. The extra glycosylation does not make SHBG bind more or
less tightly to testosterone at the steroid-binding pocket (located in the N-terminal domain).
Instead, the primary effect is on SHBG's metabolic fate: the additional sugar chain is
thought to [increase protein half-life | by masking protease cleavage sites and modulating
hepatic clearance receptors; the C-terminal domain containing this glycosylation site is also
involved in SHBG's membrane receptor interactions] in the bloodstream, resulting in higher
steady-state SHBG concentrations. Higher total SHBG means more testosterone is bound —
reducing free androgen availability even though each SHBG molecule binds testosterone with
unchanged affinity.
There is also a haplotype-level interaction: the [Thompson 2008 haplotype analysis | Thompson
et al. Cancer Epidemiol Biomarkers Prev 2008, PMID 19064566] of 11 SHBG SNPs found that the
rs6259 A allele (D356N) specifically neutralizes the SHBG-lowering effect of the rs858518/
rs727428 haplotype. When D356N is present on the same chromosomal background as the otherwise
SHBG-lowering haplotype, the expected drop in SHBG does not occur — making rs6259 a key
modifier of other SHBG variants' effects.
The Evidence
The clearest quantitative evidence comes from a 2009 study of men across three age groups |
Vanbillemont et al. Clin Endocrinol (Oxf) 2009, PMID 18681858,
which found that A allele carriers in the middle-aged cohort had 14.2% higher SHBG (P<0.001)
and 7.3% higher total testosterone (P=0.01) compared to GG homozygotes, with no significant
change in free testosterone — consistent with the body maintaining free testosterone homeostasis
through LH feedback while total SHBG rises.
A 2025 sibling study of 999 Dutch men | Walravens et al. J Clin Endocrinol Metab 2025,
PMID 38652149 confirmed that rs6259 A allele
carriers showed higher SHBG and total testosterone with no clear effect on measured free
testosterone. In the Dunning 2004 study of postmenopausal women | JNCI 2004, PMID 15199113,
D356N was significantly associated with circulating SHBG levels (P=0.005) and the
estradiol-to-SHBG ratio (P=0.01), explaining 0.6% of SHBG variance.
In the context of PCOS and metabolic syndrome, higher SHBG from the A allele appears
protective. A Chinese Han male study (n=384) | Pang et al. Aging Clin Exp Res 2014,
PMID 24671943 found A allele carriers had
significantly lower metabolic syndrome risk (OR 0.56, 95% CI 0.33–0.96) alongside higher
SHBG. A meta-analysis of 4,733 participants | Li et al. Reprod Biomed Online 2021,
PMID 33168491 found rs6259 was not significantly
associated with PCOS risk overall — consistent with the larger Liao & Cao 2020 meta-analysis
(1,660 PCOS cases, 1,312 controls, PMID 32589470) that also found no significant PCOS association.
The mechanistic expectation (higher SHBG → lower free androgen index → protective against
PCOS) is biologically plausible, but the genetic signal is not robust across all populations.
For breast cancer, a meta-analysis of 10,454 cases and 13,111 controls | Zhou et al.
Mol Biol Rep 2012, PMID 22711300 found no
significant overall association with the Asp356Asn variant, but a protective effect emerged
specifically in postmenopausal Asian women (dominant model OR 0.83, 95% CI 0.70–0.97).
A Shanghai population-based study (1,106 cases, 1,180 controls) confirmed this pattern |
Cui et al. Cancer Epidemiol Biomarkers Prev 2005, PMID 15894658,
finding OR 0.73 (95% CI 0.53–0.99) in postmenopausal women, with the strongest protection
in lean women (OR 0.46) — consistent with the A allele raising SHBG, thereby sequestering
more estradiol in the lower-estrogen postmenopausal environment.
An unexpected finding comes from prostate cancer: a Japanese study of 70 men on androgen
deprivation therapy | Shiota et al. Clin Genitourin Cancer 2019, PMID 31036465
found that A allele carriers had dramatically worse outcomes, with HR 2.20 for progression
(P=0.027) and HR 3.21 for mortality (P=0.012), despite comparable testosterone suppression
across genotypes. The mechanism remains under investigation — one hypothesis is that
higher SHBG levels in A allele carriers paradoxically maintain a reservoir of bioavailable
androgen through SHBG membrane receptor-mediated signaling, which may fuel castration-resistant
prostate cancer progression through non-classical androgen pathways.
For bone health, a study of postmenopausal women | Napoli et al. Bone 2009, PMID 19679209
found that A allele carriers had significantly lower bone mineral density at the total femur
(P=0.004) and intertrochanter (P=0.002), without detectable differences in free estradiol —
suggesting the skeletal effect may be mediated through SHBG's membrane receptor signaling
or other estrogen-independent mechanisms.
Practical Implications
For most people, rs6259 GG genotype is the common variant (approximately 79% globally).
A allele carriers — particularly AA homozygotes, who are rare (~1% of the population) —
have measurably higher SHBG and a distinct hormone profile. The practical implications
are most relevant for: (1) interpreting sex hormone panels (higher SHBG inflates total
testosterone while free testosterone may be maintained); (2) prostate cancer treatment
planning, where genotype may influence ADT response; and (3) breast cancer risk stratification
in postmenopausal Asian women.
Interactions
rs727428 and rs858518 (SHBG regulatory variants): The Thompson 2008 haplotype analysis
showed that rs6259 D356N neutralizes the SHBG-lowering haplotype formed by rs858518 and
rs727428. A person carrying the A allele at rs6259 alongside the T allele at rs727428 or
the A allele at rs858518 will partially or fully offset the expected SHBG reduction from
those regulatory variants. This is relevant for anyone carrying risk genotypes at multiple
SHBG loci — the net SHBG effect is the sum of all contributing variants, with rs6259 A
acting as a counterweight to the rs727428/rs858518 lowering effect.
rs1799941 (SHBG promoter G-68A): This promoter variant in the hormones-sleep category
also regulates SHBG levels through expression changes. Carriers of both rs1799941 A allele
(higher SHBG) and rs6259 A allele (higher SHBG) would have additive SHBG-raising effects.
For PCOS risk assessment and prostate cancer ADT planning, total SHBG genotype burden
across all four SHBG variants (rs727428, rs858518, rs1799941, rs6259) provides the most
informative picture.
Proposed interaction for supervisor review: Men with GA or AA genotype at rs6259 who
are considering or undergoing androgen deprivation therapy for prostate cancer should have
rs6259 genotype documented alongside baseline SHBG levels, as the Shiota 2019 data suggest
this may be an independent prognostic factor for ADT response regardless of testosterone
suppression depth.
Alla genotyper
Two G alleles — standard SHBG structure, no additional glycosylation site
You carry two copies of the G allele at rs6259, the most common genotype globally (approximately 79% of people). Your SHBG protein does not carry the additional N-linked glycosylation site introduced by the A allele. Your SHBG levels and free-testosterone balance are determined primarily by other factors — including your weight, insulin sensitivity, age, and the regulatory variants at rs727428, rs858518, and rs1799941 in the same gene. This is the reference genotype. No specific action is required based on this result alone.
One G and one A allele — modestly elevated SHBG, shifted hormone binding balance
You carry one copy of the A allele at rs6259. This means approximately half of your SHBG protein carries the additional N-linked glycosylation site and the other half does not. Studies show heterozygous carriers in middle age have roughly 7–14% higher SHBG than GG carriers, with total testosterone rising proportionally while free testosterone remains largely unchanged. About 19% of people globally carry this genotype (GA). The practical implication is modest in isolation: your total testosterone may appear slightly higher than expected for your age and weight, and your free androgen index slightly lower. This becomes more relevant in the context of PCOS evaluation, fertility workup, or prostate cancer treatment planning.
Two A alleles — maximum glycosylation-driven SHBG elevation, lowest free-androgen index at this locus
You carry two copies of the A allele at rs6259 — a rare genotype present in approximately 1% of the global population (more common in Europeans and East Asians, where the A allele frequency is around 12%). Both copies of your SHBG protein carry the additional N-linked glycosylation site, which is expected to produce the most pronounced elevation in circulating SHBG of the three genotypes. Higher SHBG means more testosterone is protein-bound, reducing the free-androgen fraction available to tissues. In most contexts, higher SHBG from this variant is metabolically protective — associated with lower metabolic syndrome risk, lower PCOS risk in women, and a possible protective effect against breast cancer in postmenopausal women. The notable exception is prostate cancer: men undergoing androgen deprivation therapy who carry the A allele appear to have significantly worse outcomes, making genotype disclosure to oncologists important.